Ellen Rosenberg, an insider at Amicus Therapeutics Inc (FOLD), purchased 532,710 shares of the company's stock at a price of $6.10 per share on November 23, 2025. The total transaction value reached $3.25 million.
Following this purchase, Rosenberg holds 532,710 shares of Amicus Therapeutics. The move underscores a potential confidence in the company's future, as insiders often have access to non-public information about their company's operations.
Amicus Therapeutics, based in Princeton, New Jersey, focuses on developing medicines for metabolic diseases. The company has a market capitalization of $3.1 billion and reported an EPS of -0.05. Its upcoming earnings report is scheduled for July 29, 2026, with an estimated EPS of $0.06 and revenue of $184.7 million.
While insider buying can be a positive signal, it should not be the sole factor in investment decisions. Investors are encouraged to consider broader patterns of insider activity and other fundamental metrics when evaluating stock performance.